<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03910166</url>
  </required_header>
  <id_info>
    <org_study_id>Acotec-06</org_study_id>
    <nct_id>NCT03910166</nct_id>
  </id_info>
  <brief_title>AcoArt VI / Vertebral Artery Ostium Stenosis in China</brief_title>
  <official_title>Prospective, Multi-center and Randomized Controlled Clinical Study to Verify Effectiveness and Safety of Drug-eluting Balloon in PTA Procedure of Vertebral Artery Ostium Stenosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acotec Scientific Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acotec Scientific Co., Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether DEB is not inferior to common bare metal
      stent using under in long-term vessel patency and inhibiting restenosis in Vertebral Artery
      Ostium Stenosis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vertebral Artery Origin Stenting is an established alternative to open surgical bypass for
      the treatment of Vertebral Artery Ostium Stenosis .

      DEBs are designed to promote arterial patency by reducing neointimal proliferation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 9, 2020</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>target lesion restenosis rate</measure>
    <time_frame>12Months</time_frame>
    <description>Target Lesion Restenosis（diameter stenosis ≥50%） under DSA at 12 Months or diamater stenosis ≥50% under DSA before Target Lesion Revascularization within 12 Months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>device success rate</measure>
    <time_frame>during the operation</time_frame>
    <description>DEB group:DEB catheter can reach the target lesions, expand as expected(not broken),and withdraw successfully. BES group: the stenosis rate of proximal outflow less than 50% with intervention and no ischemia or hemorrhage occurred.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of hemorrhagic stroke and posterior circulation ischemic stroke</measure>
    <time_frame>12 Months</time_frame>
    <description>incidence of hemorrhagic stroke and posterior circulation ischemic stroke within 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of transient ischemic attack of posterior circulation</measure>
    <time_frame>12 Months</time_frame>
    <description>incidence of transient ischemic attack of posterior circulation within 12 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Ischemic Stroke</condition>
  <condition>Transient Ischemic Attack</condition>
  <arm_group>
    <arm_group_label>DCB group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>use DEB catheter(trade name:Orchid/Dhalia) to treat the stenosis or occlusion in Vertebral Artery Ostium Stenosis of experimental arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>use Intracranial artery stent system(trade name:Apollo) to treat stenosis or occlusion in Vertebral Artery Ostium Stenosis of control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>drug-coated balloon catheter（Orchid, Acotec）</intervention_name>
    <description>After predilation, using drug-coated balloon catheter to cover the whole treated segment</description>
    <arm_group_label>DCB group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intracranial artery stent system（APOLLO）</intervention_name>
    <description>stent assisted angioplasty</description>
    <arm_group_label>BMS group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  aged between 18 and 80 years old

          -  symptomatic VAO stenosis refractory to best medical treatment

          -  the diameter of the normal segment of the artery beyond the stenosis between 3mm and
             5mm,Target lesion has stenosis ≥ 70% evidenced by angiography

          -  Score on the modified Rankin scale ≤ 3

          -  NIHSS≤ 6

          -  Patients have signed informed consent

        Exclusion Criteria:

          -  In-stent restenosis in vertebral artery

          -  Severe calcified lesion or residual stenosis ≥30% after predilatation or flow-limiting
             dissection

          -  Tortuous or variable vessels

          -  distal serial stenosis or distal vascular dysplasia of the stenosis segment

          -  Non-atherosclerotic arterial stenosis

          -  Non-vertebral artery stenosis caused TIA or minor stroke

          -  intracranial stent implantation within 12 months

          -  Intracranial hemorrhage occurred within 3 months

          -  Obvious thrombosis in brain vessel, patients received lysis or thrombectomy 24 hours
             before surgery

          -  Active bleeding or coagulation disorders

          -  Serious liver/kidney damage, not suitable for routine surgical treatment

          -  Patients with severe liver and kidney injury not suitable for routine surgical
             treatment

          -  Myocardial infarction or extensive cerebral infarction occurred within 2 weeks

          -  Uncontrolled high blood pressure

          -  Complicated intracranial tumor, cerebral arteriovenous malformation, or intracranial
             aneurysm

          -  Potential sources of cardiogenic thrombosis, such as mitral stenosis, atrial septal
             defect, aorta or mitral valve replacement, left atrial myxoma, etc

          -  Life expectancy shorter than 1 years

          -  Patients whit cognitive impairment or mental disorders

          -  Known hypersensitivity to aspirin, heparin, clopidogrel,paclitaxel, contrast medium,
             etc

          -  Pregnant and lactating women

          -  Patients who have participated in other clinical trials during the same period that
             lead to researchers who believe that patients may not be able to follow the trial
             program
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liqun Jiao, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Xuanwu Hospital, Beijing</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Liqun Jiao</last_name>
    <phone>13911224991</phone>
    <email>DOCTOR_K@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Xuanwu hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liqun Jiao</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>April 9, 2019</study_first_submitted>
  <study_first_submitted_qc>April 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2019</study_first_posted>
  <last_update_submitted>June 15, 2020</last_update_submitted>
  <last_update_submitted_qc>June 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>drug eluting balloon catheter</keyword>
  <keyword>stenting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemic Attack, Transient</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

